Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 4Terminated 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Leukemia, Myeloid, Acute 1Carcinoma 1

Interventions

Cyclophosphamide 98pembrolizumab 87Gemcitabine 81Carboplatin 63fludarabine 62Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 50Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 34Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26atezolizumab 25Pemetrexed 25Oxaliplatin 24Capecitabine 24fludarabine phosphate 23Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Terminated × ficlatuzumab × Clear all
NCT02109627 2020-03-24

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

University of California, San Francisco

Phase 1 Terminated
17 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02277184 2017-11-13

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

University of Pittsburgh

Phase 1 Terminated
1 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡